Alzemon: a prospective follow-up study of eslicarbazepine acetate monotherapy in patients with newly diagnosed epilepsy


Por: Hernandez L, Asensio-Asensio M, Tortosa-Conesa D, Alfaro-Sáez A, García-Escrivá A, Díaz-Román M, Montoya J, Méndez-Miralles MA, Bertol-Alegre V, Castro-Vilanova MD, Galiano ML, Blanco-Cantó ME and López-González F

Publicada: 15 abr 2021
Resumen:
Aim. To evaluate the effectiveness of eslicarbazepine as initial monotherapy in patients with newly diagnosed partial epilepsy in routine clinical practice. Patients and methods. A prospective, multicentre, post-authorisation study. Patients with newly diagnosed partial epilepsy aged 18 years or older without previous treatment were included. The efficacy variables were: percentage of seizure-free patients, responders and reduction in monthly frequency of seizures. The safety variables analyse the 12-month retention rate and the occurrence of adverse effects. Results. Fifty-three patients were included. The retention rate was 77.4%. At the end of the observation period, 83% of patients were seizure-free and 92.5% had reduced their baseline frequency by 50% or more. In addition, 68% of the patients reported some adverse effect and 7.5% of them dropped out of the study for this reason. The effectiveness analysis of the subgroup of patients aged 65 years or more showed no differences with respect to the overall population. Conclusion. Eslicarbazepine monotherapy in patients with newly diagnosed partial epilepsy, both in the general population and in the population over 65 years old, is effective and safe in routine clinical practice.

Filiaciones:
Hernandez L:
 Hospital General Universitario de Elda, 03600 Elda, España

Asensio-Asensio M:
 Hospital General Universitario de Alicante, Alicante, España

Tortosa-Conesa D:
 Hospital Universitario Virgen de la Arrixaca, El Palmar, España

:
 Hospital Vega Baja, 03314 Orihuela, España

 Universidad Miguel Hernández, Elche, España

:
 Hospital Marina Salud, Denia, España

:
 Hospital Lluís Alcanyís de Xàtiva, Xàtiva, España

Montoya J:
 Hospital General Universitario de Valencia, Valencia, España

:
 Hospital Universitario de Torrevieja, Torrevieja, España

Bertol-Alegre V:
 HUMS. Hospital Universitario Miguel Servet, 50009 Zaragoza, España

Castro-Vilanova MD:
 Complejo Hospitalario Universitario de Vigo, 36200 Vigo, España

Galiano ML:
 Hospital Universitario Gregorio Marañón, Madrid, España

Blanco-Cantó ME:
 Hospital Marina Salud, Denia, España

López-González F:
 Hospital General Universitario de Alicante, Alicante, España
ISSN: 15766578





REVISTA DE NEUROLOGIA
Editorial
REVISTA DE NEUROLOGIA, C/O CESAR VIGUERA, EDITOR, APDO 94121, 08080 BARCELONA, SPAIN, España
Tipo de documento: Article
Volumen: 72 Número: 8
Páginas: 263-268
WOS Id: 000640937400001
ID de PubMed: 33851715

MÉTRICAS